Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting radioresistance and replication fork stability in prostate cancer.
Li X, Baek G, Carreira S, Yuan W, Ma S, Hofstad M, Lee S, Gao Y, Bertan C, Fenor de la Maza MLD, Alluri PG, Burma S, Chen BP, Raj GV, de Bono J, Pommier Y, Mani RS. Li X, et al. Among authors: fenor de la maza mld. JCI Insight. 2022 May 9;7(9):e152955. doi: 10.1172/jci.insight.152955. JCI Insight. 2022. PMID: 35349486 Free PMC article.
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.
Westaby D, Fenor de La Maza MLD, Paschalis A, Jimenez-Vacas JM, Welti J, de Bono J, Sharp A. Westaby D, et al. Among authors: fenor de la maza mld. Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:131-153. doi: 10.1146/annurev-pharmtox-052220-015912. Epub 2021 Aug 24. Annu Rev Pharmacol Toxicol. 2022. PMID: 34449248 Review.
Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.
Donners R, Fotiadis N, Figueiredo I, Blackledge M, Westaby D, Guo C, Fenor de la Maza MLD, Koh DM, Tunariu N. Donners R, et al. Among authors: fenor de la maza mld. Eur Radiol. 2022 Oct;32(10):6820-6829. doi: 10.1007/s00330-022-09011-y. Epub 2022 Jul 26. Eur Radiol. 2022. PMID: 35881184 Free PMC article.
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.
Westaby D, Jiménez-Vacas JM, Figueiredo I, Rekowski J, Pettinger C, Gurel B, Lundberg A, Bogdan D, Buroni L, Neeb A, Padilha A, Taylor J, Zeng W, Das S, Hobern E, Riisnaes R, Crespo M, Miranda S, Ferreira A, Hanratty BP, Nava Rodrigues D, Bertan C, Seed G, Fenor de La Maza MLD, Guo C, Carmichael J, Grochot R, Chandran K, Stavridi A, Varkaris A, Stylianou N, Hollier BG, Tunariu N, Balk SP, Carreira S, Yuan W, Nelson PS, Corey E, Haffner M, de Bono J, Sharp A. Westaby D, et al. Among authors: fenor de la maza mld. J Clin Invest. 2024 Sep 17;134(18):e179998. doi: 10.1172/JCI179998. J Clin Invest. 2024. PMID: 39286979 Free PMC article.
RNASEH2B loss and PARP inhibition in advanced prostate cancer.
Carmichael J, Figueiredo I, Gurel B, Beije N, Yuan W, Rekowski J, Seed G, Carreira S, Bertan C, Fenor de La Maza MLD, Chandran K, Neeb A, Welti J, Gallagher L, Bogdan D, Crespo M, Riisnaes R, Ferreira A, Miranda S, Lu J, Shen MM, Hall E, Porta N, Westaby D, Guo C, Grochot R, Lord CJ, Mateo J, Sharp A, de Bono J. Carmichael J, et al. Among authors: fenor de la maza mld. J Clin Invest. 2024 Jun 4;134(21):e178278. doi: 10.1172/JCI178278. J Clin Invest. 2024. PMID: 38833311 Free PMC article. Clinical Trial.